Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Kuang-Ming Liao, Jhi-Joung Wang & Chung-Han Ho. (2023) Real-World Experience of Treating Chronic Obstructive Pulmonary Disease with Triple Therapy. International Journal of Chronic Obstructive Pulmonary Disease 18, pages 1057-1066.
Read now
Read now
Wei-Chun Huang, Chih-Yu Chen, Wei-Chih Liao, Biing-Ru Wu, Wei-Chun Chen, Chih-Yen Tu, Chia-Hung Chen & Wen-Chien Cheng. (2021) A Real World Study to Assess the Effectiveness of Switching to Once Daily Closed Triple Therapy from Mono/Dual Combination or Open Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. International Journal of Chronic Obstructive Pulmonary Disease 16, pages 1555-1568.
Read now
Read now
Giulia Parri, Dario Nieri, Maria Adelaide Roggi, Barbara Vagaggini, Alessandro Celi & Pierluigi Paggiaro. (2018) Fluticasone furoate, umeclidinium bromide, and vilanterol as a combination therapy for chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 12:12, pages 997-1005.
Read now
Read now
Lowie Vanfleteren, Leonardo M Fabbri, Alberto Papi, Stefano Petruzzelli & Bartolome Celli. (2018) Triple therapy (ICS/LABA/LAMA) in COPD: time for a reappraisal. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 3971-3981.
Read now
Read now
Edward M Kerwin, Thomas M Siler, Samir Arora, Patrick Darken, Earl Rose$suffix/text()$suffix/text() & Colin Reisner. (2018) Efficacy, safety, and pharmacokinetics of budesonide/formoterol fumarate delivered via metered dose inhaler using innovative co-suspension delivery technology in patients with moderate-to-severe COPD. International Journal of Chronic Obstructive Pulmonary Disease 13, pages 1483-1494.
Read now
Read now
Douglas Mapel, François Laliberté, Melissa H Roberts, Susan R Sama, Devi Sundaresan, Dominic Pilon, Patrick Lefebvre, Mei Sheng Duh & Jeetvan Patel. (2017) A retrospective study to assess clinical characteristics and time to initiation of open-triple therapy among patients with chronic obstructive pulmonary disease, newly established on long-acting mono- or combination therapy. International Journal of Chronic Obstructive Pulmonary Disease 12, pages 1825-1836.
Read now
Read now
Janice A. Dye, Eugene A. Gibbs-Flournoy, Judy H. Richards, Joel Norwood, Katherine Kraft & Gary E. Hatch. (2017) Neonatal rat age, sex and strain modify acute antioxidant response to ozone. Inhalation Toxicology 29:7, pages 291-303.
Read now
Read now
Articles from other publishers (39)
Jonathan Marshall, Akanksha Sharma, Patrick Darken, Mario Ouwens, Barinder Singh & Deniz Tansey-Dwyer. (2023) Letter to the Editor Regarding “Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis”. Advances in Therapy 40:5, pages 2549-2555.
Crossref
Crossref
Mingjin Yang, Yishi Li, Youfan Jiang, Shuliang Guo, Jian-Qing He & Don D. Sin. (2023) Combination therapy with long-acting bronchodilators and the risk of major adverse cardiovascular events in patients with COPD: a systematic review and meta-analysis. European Respiratory Journal 61:2, pages 2200302.
Crossref
Crossref
Chienhsiu Huang, Sufang Kuo, Lichen Lin & Yalun Yang. (2023)
The efficacy of
N
-acetylcysteine in chronic obstructive pulmonary disease patients: a meta-analysis
. Therapeutic Advances in Respiratory Disease 17, pages 175346662311585.
Crossref
Crossref
Bernardino Alcázar-Navarrete, Lucía Jamart, Joaquín Sánchez-Covisa, Mónica Juárez, Ruth Graefenhain & Antoni Sicras-Mainar. (2022) Clinical Characteristics, Treatment Persistence, and Outcomes Among Patients With COPD Treated With Single- or Multiple-Inhaler Triple Therapy: A Retrospective Analysis in Spain. CHEST 162:5, pages 1017-1029.
Crossref
Crossref
Hyun Woo Lee, Hee Moon Park, Eun Jin Jang & Chang-Hoon Lee. (2022) Different inhaled corticosteroid doses in triple therapy for chronic obstructive pulmonary disease: systematic review and Bayesian network meta-analysis. Scientific Reports 12:1.
Crossref
Crossref
Gabriela Fischer, Francisco B. de Queiroz, Danilo C. Berton, Pedro Schons, Henrique B. Oliveira, Marcelo Coertjens, Mathieu Gruet & Leonardo A. Peyré-Tartaruga. (2021) Factors influencing self-selected walking speed in fibrotic interstitial lung disease. Scientific Reports 11:1.
Crossref
Crossref
Arnaud Bourdin, Nicolas Molinari, Gary T. Ferguson, Barinder Singh, Mohd Kashif Siddiqui, Ulf Holmgren, Mario Ouwens, Martin Jenkins & Enrico De Nigris. (2021) Efficacy and Safety of Budesonide/Glycopyrronium/Formoterol Fumarate versus Other Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy 38:6, pages 3089-3112.
Crossref
Crossref
Corrado Pelaia, Giada Procopio, Maria Rosaria Deodato, Olivia Florio, Angelantonio Maglio, Angela Sciacqua, Alessandro Vatrella & Girolamo Pelaia. (2021) Real-Life Clinical and Functional Effects of Fluticasone Furoate/Umeclidinium/Vilanterol-Combined Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease. Respiration 100:2, pages 127-134.
Crossref
Crossref
Gary T. Ferguson, Patrick Darken, Shaila Ballal, Mohd Kashif Siddiqui, Barinder Singh, Sumeet Attri, Ulf Holmgren & Enrico de Nigris. (2020) Efficacy of Budesonide/Glycopyrronium/Formoterol Fumarate Metered Dose Inhaler (BGF MDI) Versus Other Inhaled Corticosteroid/Long-Acting Muscarinic Antagonist/Long-Acting β2-Agonist (ICS/LAMA/LABA) Triple Combinations in COPD: A Systematic Literature Review and Network Meta-analysis. Advances in Therapy 37:6, pages 2956-2975.
Crossref
Crossref
Hana Müllerová, Mark T. Dransfield, Byron Thomashow, Paul W. Jones, Stephen Rennard, Niklas Karlsson, Malin Fageras, Norbert Metzdorf, Stefano Petruzzelli, Jean Rommes, Frank C. Sciurba, Maggie Tabberer, Debora Merrill & Ruth Tal-Singer. (2020) Clinical Development and Research Applications of the Chronic Obstructive Pulmonary Disease Assessment Test. American Journal of Respiratory and Critical Care Medicine 201:9, pages 1058-1067.
Crossref
Crossref
Sanjay Sethi, James F. Donohue, Gary T. Ferguson, Chris N. Barnes & Glenn D. Crater. (2020) Efficacy and safety of revefenacin for nebulization in patients with chronic obstructive pulmonary disease taking concomitant ICS/LABA or LABA: subgroup analysis from phase III trials. Therapeutic Advances in Respiratory Disease 14, pages 175346662090527.
Crossref
Crossref
Yazan Zayed, Mahmoud Barbarawi, Babikir Kheiri, Tarek Haykal, Adam Chahine, Laith Rashdan, Kewan Hamid, Saira Sundus, Momen Banifadel, Ahmed Aburahma, Ghassan Bachuwa & Arul Chandran. (2019) Triple versus dual inhaler therapy in moderate‐to‐severe COPD: A systematic review and meta‐analysis of randomized controlled trials. The Clinical Respiratory Journal 13:7, pages 413-428.
Crossref
Crossref
Luigino Calzetta, Mario Cazzola, Maria Gabriella Matera & Paola Rogliani. (2019) Adding a LAMA to ICS/LABA Therapy. Chest 155:4, pages 758-770.
Crossref
Crossref
Andrea Maes, Paolo DePetrillo, Shahid Siddiqui, Colin Reisner & Paul Dorinsky. (2018) Pharmacokinetics of Co‐Suspension Delivery Technology Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate (BGF MDI) and Budesonide/Formoterol Fumarate Dihydrate (BFF MDI) Fixed‐Dose Combinations Compared With an Active Control: A Phase 1, Randomized, Single‐Dose, Crossover Study in Healthy Adults. Clinical Pharmacology in Drug Development 8:2, pages 223-233.
Crossref
Crossref
Juan Carlos Vázquez-García, Rafael de Jesús Hernández-Zenteno, José Rogelio Pérez-Padilla, María del Carmen Cano-Salas, Margarita Fernández-Vega, Jorge Salas-Hernández, Marco Antonio Figueroa-Morales, Rosaura Esperanza Benítez-Pérez, Luis Adrián Rendón-Pérez, Jesús Vázquez-Cortés, Mayra Edith Mejía-Ávila, José Luis Mayorga-Butrón, Moisés Acuña-Kaldman, Rocío Barriga-Acevedo, Alma Rosa Bizarrón-Muro, Robert Camargo-Ángeles, Catalina Casillas-Suárez, Celia Oralia Castañeda-Hernández, Rafael Patricio Castañón-Rodríguez, Juan Francisco Castillo-Sánchez, Arturo Cortés-Télles, Jesús Javier Díaz-Castañón, Abelardo Elizondo Ríos, María Guadalupe Espitia-Hernández, Martha Angélica García-Avilés, Rogelio García-Torrentera, Julio Edgardo González Aguirre, Fernando Carlos Guillén-Ortega, José Carlos Herrera-García, Marco Antonio Loustaunau-Andrade, Gerardo Ezequiel Magdaleno Maldonado, Luz Audina Mendoza Topete, José Padua-García, Andrés Palomar-Lever, Rafael Francisco Páramo-Arroyo, Saraí del Carmen Toral-Freyre, José Felipe Villegas-Elizondo & Edgar Gerardo Zozoaga-Velázquez. (2019) Guía de Práctica Clínica Mexicana para el diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica <br>GUÍA MEXICANA DE EPOC, 2020. NCT Neumología y Cirugía de Tórax 78:S1, pages 4-76.
Crossref
Crossref
Maurice Driessen, Dhvani Shah, Nancy Risebrough, Timothy Baker, Ian Naya, Andrew Briggs & Afisi S. Ismaila. (2018) Cost-effectiveness of umeclidinium as add-on to ICS/LABA therapy in COPD: A UK perspective. Respiratory Medicine 145, pages 130-137.
Crossref
Crossref
Michael Bogart, Mrudula B. Glassberg, Tyler Reinsch & Richard H. Stanford. (2018) Impact of prompt versus delayed initiation of triple therapy post COPD exacerbation in a US-managed care setting. Respiratory Medicine 145, pages 138-144.
Crossref
Crossref
Yayuan Zheng, Jianhong Zhu, Yuyu Liu, Weiguang Lai, Chunyu Lin, Kaifen Qiu, Junyan Wu & Weimin Yao. (2018) Triple therapy in the management of chronic obstructive pulmonary disease: systematic review and meta-analysis. BMJ, pages k4388.
Crossref
Crossref
Ian P. Naya, Lee Tombs, David A. Lipson & Chris Compton. (2018) Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis. Advances in Therapy 35:10, pages 1626-1638.
Crossref
Crossref
Michael Bogart, Richard H. Stanford, Tyler Reinsch, Michael Hull, Ami Buikema & Erin Hulbert. (2018) Clinical characteristics and medication patterns in patients with COPD prior to initiation of triple therapy with ICS/LAMA/LABA: A retrospective study. Respiratory Medicine 142, pages 73-80.
Crossref
Crossref
Beth Hahn, Michael Hull, Cori Blauer-Peterson, Ami R. Buikema, Riju Ray & Richard H. Stanford. (2018) Rates of escalation to triple COPD therapy among incident users of LAMA and LAMA/LABA. Respiratory Medicine 139, pages 65-71.
Crossref
Crossref
Patrick Darken, Paolo DePetrillo, Colin Reisner, Earl St Rose & Paul Dorinsky. (2018) The pharmacokinetics of three doses of budesonide/glycopyrronium/formoterol fumarate dihydrate metered dose inhaler compared with active controls: A Phase I randomized, single-dose, crossover study in healthy adults. Pulmonary Pharmacology & Therapeutics 50, pages 11-18.
Crossref
Crossref
Gary T. Ferguson, Anthony J. Hickey & Sarvajna Dwivedi. (2018) Co-suspension delivery technology in pressurized metered-dose inhalers for multi-drug dosing in the treatment of respiratory diseases. Respiratory Medicine 134, pages 16-23.
Crossref
Crossref
Maggie Tabberer, David A. Lomas, Ruby Birk, Noushin Brealey, Chang-Qing Zhu, Steve Pascoe, Nicholas Locantore & David A. Lipson. (2018) Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life. Advances in Therapy 35:1, pages 56-71.
Crossref
Crossref
Mònica Aparici, Carla Carcasona, Israel Ramos, José Luís Montero, José Luís Ortiz, Julio Cortijo, Carlos Puig, Dolors Vilella, Chris Doe, Amadeu Gavaldà & Montserrat Miralpeix. (2017) Pharmacological preclinical characterization of LAS190792, a novel inhaled bifunctional muscarinic receptor antagonist /β 2 -adrenoceptor agonist (MABA) molecule. Pulmonary Pharmacology & Therapeutics 46, pages 1-10.
Crossref
Crossref
E. N. Barabanova. (2017) GOLD 2017: what change were made in global strategy of treatment of chronic obstructive pulmonary disease and why?. PULMONOLOGIYA 27:2, pages 274-282.
Crossref
Crossref
Han Ni, Aung Htet & Soe Moe. (2017) Umeclidinium bromide versus placebo for people with chronic obstructive pulmonary disease (COPD). Cochrane Database of Systematic Reviews 2017:6.
Crossref
Crossref
Marc Miravitlles, Juan José Soler-Cataluña, Myriam Calle, Jesús Molina, Pere Almagro, José Antonio Quintano, Juan Antonio Trigueros, Borja G. Cosío, Ciro Casanova, Juan Antonio Riesco, Pere Simonet, David Rigau, Joan B. Soriano & Julio Ancochea. (2017) Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Archivos de Bronconeumología 53:6, pages 324-335.
Crossref
Crossref
Marc Miravitlles, Juan José Soler-Cataluña, Myriam Calle, Jesús Molina, Pere Almagro, José Antonio Quintano, Juan Antonio Trigueros, Borja G. Cosío, Ciro Casanova, Juan Antonio Riesco, Pere Simonet, David Rigau, Joan B. Soriano & Julio Ancochea. (2017) Spanish COPD Guidelines (GesEPOC) 2017. Pharmacological Treatment of Stable Chronic Obstructive Pulmonary Disease. Archivos de Bronconeumología (English Edition) 53:6, pages 324-335.
Crossref
Crossref
. (2017) Tratamiento de la EPOC Estable. Archivos de Bronconeumología 53, pages 23-33.
Crossref
Crossref
Myriam Amsallem, David Boulate, Zoe Kooreman, Roham T. Zamanian, Guillaume Fadel, Ingela Schnittger, Elie Fadel, Michael V. McConnell, Gundeep Dhillon, Olaf Mercier & François Haddad. (2017) Investigating the value of right heart echocardiographic metrics for detection of pulmonary hypertension in patients with advanced lung disease. The International Journal of Cardiovascular Imaging 33:6, pages 825-835.
Crossref
Crossref
Leonardo M Fabbri, Sara Roversi & Bianca Beghé. (2017) Triple therapy for symptomatic patients with COPD. The Lancet 389:10082, pages 1864-1865.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez‐Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report. Respirology 22:3, pages 575-601.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M.G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agusti. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. European Respiratory Journal 49:3, pages 1700214.
Crossref
Crossref
Claus F. Vogelmeier, Gerard J. Criner, Fernando J. Martinez, Antonio Anzueto, Peter J. Barnes, Jean Bourbeau, Bartolome R. Celli, Rongchang Chen, Marc Decramer, Leonardo M. Fabbri, Peter Frith, David M. G. Halpin, M. Victorina López Varela, Masaharu Nishimura, Nicolas Roche, Roberto Rodriguez-Roisin, Don D. Sin, Dave Singh, Robert Stockley, Jørgen Vestbo, Jadwiga A. Wedzicha & Alvar Agustí. (2017) Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report. GOLD Executive Summary. American Journal of Respiratory and Critical Care Medicine 195:5, pages 557-582.
Crossref
Crossref
Joy Creaser-Thomas, Vignesh Rajasundaram & Gwyneth A Davies. 2017. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions. A Worldwide Yearly Survey of New Data in Adverse Drug Reactions
161
171
.
M. Zysman, F. Chabot, P. Devillier, B. Housset, C. Morelot-Panzini & N. Roche. (2016) Pharmacological treatment optimization for stable chronic obstructive pulmonary disease. Proposals from the Société de Pneumologie de Langue Française. Revue des Maladies Respiratoires 33:10, pages 911-936.
Crossref
Crossref
Paolo Montuschi, Mario Malerba, Giuseppe Macis, Nadia Mores & Giuseppe Santini. (2016) Triple inhaled therapy for chronic obstructive pulmonary disease. Drug Discovery Today 21:11, pages 1820-1827.
Crossref
Crossref
Thomas M. Siler, Edward Kerwin, Lee Tombs, William A. Fahy & Ian Naya. (2016) Triple Therapy of Umeclidinium + Inhaled Corticosteroids/Long-Acting Beta2 Agonists for Patients with COPD: Pooled Results of Randomized Placebo-Controlled Trials. Pulmonary Therapy 2:1, pages 43-58.
Crossref
Crossref